SALT LAKE CITY, July 18, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a worldwide leader in personalized medicine, today announced that Kroger Prescription Plans, will provide  Vectra^® DA as a benefit option for Kroger Prescription Plan employer group clients.   

“The cost of care for patients with rheumatoid arthritis has skyrocketed and specialty drugs to treat autoimmune diseases now comprise approximately ten percent of pharmacy spending in the United States,” said Rich Adams, senior vice president at Kroger Prescription Plans.  “Vectra DA has demonstrated the ability to improve patient outcomes while optimizing pharmaceutical spending which makes it a highly attractive diagnostic test for our members.”

“We are excited to work with organizations such as Kroger Prescription Plans who are in an ideal position to recognize the value driven by our pioneering diagnostic tests,” said Chip Parkinson, executive vice president of Payer Markets at Myriad Genetics. “Employers are in the best position to realize the promise of personalized medicine by improving employee wellness and reducing their healthcare costs.”

Myriad Genetics and Kroger Prescription Plans are also in late stage discussions on implementing a similar program for GeneSight, Myriad’s proprietary test for aiding in the selection of psychotropic medicines for patients with major depressive disorder.

About Vectra^® DA
Vectra DA is the only validated multi-biomarker molecular blood test that simultaneously measures 12 key biomarkers to provide an objective and personalized measure of rheumatoid arthritis (RA) disease activity. Vectra DA is the best test at predicting radiographic progression and provides scores ranged from 1 to 100 to categorize RA disease activity into low, moderate or high to guide medical management.  For more information, please visit: www.vectra-da.com.

About Kroger Prescription Plans
Kroger Prescription Plans is dedicated to providing pharmacy benefit management services and innovative clinical programs that focus on engagement, choice, and cost savings.  Built on personalized care solutions that simplify health, wellness and nutrition, Kroger Prescription Plans is the catalyst to combining a full suite of Kroger entities to improve health and deliver savings.  The company provides pharmacy benefit management services to a wide range of employers across 32 states, including The Kroger Co., the 4th-largest employer in the United States.  Discover more at www.kpp-rx.com.

About Myriad Genetics
Myriad Genetics Inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics.  Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs.  Myriad is focused on five strategic imperatives:  build upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020.  For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Safe Harbor Statement
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Kroger Prescription Plans providing the Company’s  Vectra® DA test as an benefit option for Kroger Prescription Plan employer group clients;  the Company and Kroger Prescription Plans implementing a similar program for GeneSight, the Company’s proprietary test for aiding in the selection of psychotropic medicines for patients with major depressive disorder; and the Company’s strategic directives under the caption “About Myriad Genetics.”  These “forward-looking statements” are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those described or implied in the forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers’ reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire, including but not limited to our acquisition of Assurex, Sividon and the Clinic; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decision in the lawsuit brought against us by the Association for Molecular Pathology et al; risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements;  the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading “Risk Factors” contained in Item 1A of our Annual report on Form 10-K for our most recent fiscal year ended, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K.

Media Contact:		Ron Rogers		Investor Contact:		Scott Gleason
		(801) 584-3065				(801) 584-1143
		rrogers@myriad.com				sgleason@myriad.com